Shares of Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $14.21, but opened at $13.51. Astellas Pharma shares last traded at $13.40, with a volume of 3,399 shares.
Analyst Upgrades and Downgrades
A number of equities research analysts have commented on ALPMY shares. Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Finally, Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a report on Monday, February 16th. One analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold”.
View Our Latest Report on Astellas Pharma
Astellas Pharma Stock Up 0.1%
Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last released its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.14. Astellas Pharma had a net margin of 13.66% and a return on equity of 24.19%. The business had revenue of $3.38 billion for the quarter, compared to analyst estimates of $3.28 billion. On average, equities research analysts predict that Astellas Pharma Inc. will post 1.29 EPS for the current year.
About Astellas Pharma
Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.
Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).
Further Reading
- Five stocks we like better than Astellas Pharma
- Wall Street Is Starting to Talk About Tesla’s Endgame
- Meta’s Manus Mess: Why China Blocked the Deal and What It Means
- China Deal Ignites Boeing’s Financial Afterburners
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
